NEW MJ NEWS

AbbVie to Host Third-Quarter 2023 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-third-quarter-2023-earnings-conference-call-301942331.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

4Front Ventures Corp. (FFNTF) to Report Third Quarter 2022 Financial Results on November 14, 2022

4Front Ventures to Report Third Quarter 2022 Financial Results on November 14,…

Emblem Corp. (EMMBF) Announces $3 Million Strategic Equity Investment in Natura Naturals

Emblem Announces $3 Million Strategic Equity Investment in Natura Naturals and 9,000…

 The Green Organic Dutchman Holdings Ltd. (TGOD) (TGODF) Signs Letter of Intent with Quebec’s SQDC

The Green Organic Dutchman Signs Letter of Intent with Quebec’s SQDC  …

$NVLX Gets Exclusive Worldwide License To Use Unique Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine For Treatment Development

Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R)…